Pfizer Inc vs Personalis Inc. Common Stock — how do they compare? Pfizer Inc trades at $29.48 (market cap $161.70B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B). The key difference: Pfizer Inc is far larger — about 95.7× Personalis Inc. Common Stock's market cap, and Pfizer Inc pays a 6.06% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Personalis Inc. Common Stock for 0 Days on average.
| PFE | PSNL | |
|---|---|---|
Market Cap | $161.70B | $1.69B |
Volume | 26,828,084 | 3,817,236 |
Sector | Health | Health |
52-Week High | $29.21 | $18.38 |
52-Week Low | $23.67 | $5.04 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $213.20B | $1.52B |
Dividend Yield | 6.06% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →